Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or those diagnosed with multiple endocrine neoplasia syndrome type 2, due to a theoretical risk of thyroid tumors based on animal studies
The once-weekly dosing also simplifies the treatment regimen, potentially increasing adherence and enhancing quality of life
In either case, follow-up care matters
Dizziness or lightheadedness affects about 8% to 10%, often related to reduced food intake, dehydration, or blood pressure changes from weight loss
US$ 28.69
US$ 24.68
US$ 28.61
US$ 22.86
US$ 26.45
US$ 23.98
